Cure rate of childhood B cell lymphoma with rituximab and reduced strength of chemotherapy

Rituximab with reduced dosage LMB backbone chemotherapy schedule in childhood and adolescent mature B cell lymphoma/leukemia: Evaluation of efficacy & toxicity profile in developing country setting - R LMB childhood lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/09/009650

Enrollment

Registered

2017-09-05

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Burkitt lymphoma and diffuse large B cell lymphoma

Interventions

Intervention1: Rituximab: Intravenour rituximab will be administered with every cycle of chemotherapy. The dose will be 375mg/m2. Total of 4 doses of rituximab will be administered at a frequency of 2

Eligibility

Inclusion criteria

Inclusion criteria: 1. CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage III & IV stage 2. CD 20 positive Burkitt lymphoma & Diffuse large B cell lymphoma stage I & II stage non-resectable

Exclusion criteria

Exclusion criteria: 1. Active hepatitis B infection or carriers of hepatitis B virus 2. Active hepatitis C infection or carriers of hepatitis C virus 3. HIV infected children 4. Patients with congenital immunodeficiency, chromosomal breakage syndrome, prior organ transplantation, previous malignancy of any type, or known positive HIV serology 5. Follicular lymphoma, MALT, nodular marginal zone lymphoma and primary mediastinal B cell lymphoma 6. Children with cardiac dysfunction- ejection fraction 7. Pregnancy 8. Allergic to rituximab 9. Not consenting for treatment 10. Children assessed by treating physician as not fit for intensive chemotherapy

Design outcomes

Primary

Measure	Time frame
To evaluate the efficacy of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.Timepoint: To evaluate the efficacy of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.	—

Secondary

Measure	Time frame
To evaluate the toxicity profile of treatment schedule utilizing addition of rituximab to reduced dosage standard LMB backbone chemotherapy.Timepoint: During chemotherapy treatment	—

Countries

India

Contacts

Public ContactJaikumar GR

Cancer Institute Adyar

gr_jaikumar@yahoo.in8196800157

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026